Small Pharma To Announce Results of SPL026 Phase IIa Trial for Major Depressive Disorder and Host Conference Call on Wednesday, January 25

Rhea-AI Summary

Small Pharma Inc. (TSXV: DMT, OTCQB: DMTTF) announced the upcoming release of top-line data from its Phase IIa trial of SPL026 for Major Depressive Disorder (MDD) on January 25, 2023. The results will be disclosed before market open, and a conference call will be held at 8:30 AM EST / 1:30 PM GMT on the same day to discuss the findings. SPL026 is a proprietary synthetic formulation of DMT and has received Innovation Passport designation from the U.K. Medicines and Healthcare products Regulatory Agency for MDD treatment. The company is advancing its clinical programs alongside developing a portfolio of preclinical assets.

Positive

• Announcement of top-line data from Phase IIa trial of SPL026 for MDD, which may indicate progress in therapy development.
• SPL026 received Innovation Passport designation from the MHRA, suggesting regulatory support and potential expedited development.

Negative

• None.

LONDON, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today announces that it will release top-line data from its Phase IIa trial of SPL026 in Major Depressive Disorder (“MDD”) prior to market-open tomorrow on Wednesday, January 25, 2023.

The Small Pharma management team will host a conference call at 8:30am EST / 1:30pm GMT on Wednesday January 25, 2023. To access the call and webcast presentation, select the relevant dial-in number and webcast link below.

Conference Call and Webcast Details:

Time:	8:30 a.m. (EST) / 1:30 p.m. (GMT)
Investors Dial:	+1-877-423-9813
International Investors Dial:	+1-201-689-8573
Conference ID:	13735973
Webcast (with slides):	https://viavid.webcasts.com/starthere.jsp?ei=1595427&tp_key=af827d4034

Following its completion, the webcast will be available on the Investor section of the Small Pharma website under ‘Events & Conferences’. The webcast will be available for 30 days.

About Small Pharma

Small Pharma is a biotechnology company progressing a pipeline of short-duration psychedelic-assisted therapies for the treatment of mental health conditions. The Company’s current focus is on exploring new therapeutic approaches for depression. Small Pharma’s lead candidate, SPL026, is a proprietary synthetic formulation of DMT. The Company is advancing clinical programs of SPL026 with supportive therapy for the treatment of mental health conditions and was granted an Innovation Passport designation from the U.K. Medicines and Healthcare products Regulatory Agency (the “MHRA”) for intravenous SPL026 with supportive therapy for MDD. In addition, Small Pharma has a pipeline of proprietary preclinical assets in development.

For further information contact:

Small Pharma Inc.
George Tziras, Chief Executive Officer
Email: ir@smallpharma.co.uk
Tel: +1 (646) 751-4363

Investor Relations Contacts:
Eric Ribner
LifeSci Advisors
Email: eric@lifesciadvisors.com
Tel: +1 (646) 889-1200

Media Relations Contacts:
Jaber Mohamed
MHP Communications
Email: smallpharma@mhpc.com
Tel: +44 (0)7720 326 847

Cautionary Note

Small Pharma makes no medical, treatment or health benefit claims about its proposed products. The MHRA or other similar regulatory authorities have not evaluated claims regarding its therapies and other next generation psychoactive compounds. The efficacy of such therapies has not been confirmed by MHRA-approved research. There is no assurance that such therapies and other psychoactive compounds can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. Any references to quality, consistency, efficacy and safety of potential therapies do not imply that Small Pharma verified such in clinical trials or that Small Pharma will complete such trials. If Small Pharma cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Small Pharma’s performance and operations.

The TSX Venture Exchange (“TSXV”) has neither approved nor disapproved the contents of this news release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

FAQ

When will Small Pharma release the top-line data for SPL026?

Small Pharma will release the top-line data from its Phase IIa trial of SPL026 for Major Depressive Disorder on January 25, 2023.

What is SPL026 used for?

SPL026 is being developed as a treatment for Major Depressive Disorder (MDD) and is a synthetic formulation of DMT.

What time is the conference call for the SPL026 trial results?

The conference call to discuss the SPL026 trial results will take place at 8:30 AM EST / 1:30 PM GMT on January 25, 2023.

What regulatory designation has SPL026 received?

SPL026 has received an Innovation Passport designation from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA).

Where can I access the webcast of the conference call?

The webcast of the conference call can be accessed through the Small Pharma Investor section on their website.